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Prostate cancer is a common malignancy and
a leading cause of cancer death in the United
States (Crawford 2003). The molecular
mechanisms underlying its development and
progression remain poorly understood.
Prostate cancer usually begins as an andro-
gen-dependent tumor that may undergo clin-
ical regression in response to pharmacologic
or surgical strategies that reduce circulating
testosterone concentrations or block andro-
gen actions (Kyprianou and Isaacs 1988).
Despite this treatment, prostate tumors often
reappear as androgen-independent or hor-
mone-refractory cancers (Westin and Bergh
1998). The molecular basis for this acquired
androgen independence is poorly deﬁned. 
Most androgen-independent prostate
tumors overexpress androgen receptor (AR) as
well as androgen-activated gene products such
as prostate-specific antigen (PSA) (Kim and
Coetzee 2004). In fact, hormone-refractory
prostate cancer cells often can maintain func-
tional AR signaling despite greatly reduced lev-
els of circulating testosterone as, for instance,
with orchiectomy (Deutsch et al. 2004)
because of AR overexpression. High levels of
AR can correlate with prostatic cancer progres-
sion in many cases (Lee and Tenniswood
2004), and AR gene ampliﬁcation is observed
in 20–30% of all hormone-refractory prostate
cancers (Linja et al. 2001). A role for AR in
prostate cancer progression is supported by
the correlation between its overexpression and
the expression of androgen-regulated genes
(Gregory et al. 1998). Up-regulation of AR
clearly increases sensitivity to low androgen
levels, leading to ligand-dependent down-
stream androgen-regulated gene expression
and prostate tumor recurrence. In fact, the
term “androgen-independent” prostate cancer
is somewhat of a misnomer, because it often
involves androgen hypersensitivity rather than
true independence (Gregory et al. 2001).
There are also mechanisms for AR activa-
tion in recurrent or advanced prostate cancers
in which overexpression is not obligatory.
These include altered growth factor–induced
phosphorylation (Craft et al. 1999; Sadar
et al. 1999) and AR mutations that broaden
ligand speciﬁcity (Newmark et al. 1992; Tan
et al. 1997). Indeed, some hormone-refrac-
tory prostate cancers appear to recruit non-
steroidal signal transduction pathways that
activate AR even in the face of severe andro-
gen deprivation (Taplin and Balk 2004).
Thus, a “by-pass” of the requirement for
androgen to interact with AR for activation of
downstream events can occur in prostate can-
cer with acquired androgen independence
(Feldman and Feldman 2001; Gleave et al.
1999). Indeed, HER-2/neu, a member of the
EGF-receptor family of receptor tyrosine
kinase, can activate AR-dependent genes in the
absence of AR-ligand interactions (Culig et al.
1994; Yeh et al. 1999). In fact, HER-2/neu,
when overexpressed, not only activates the AR
pathway in the absence of ligand but also
synergizes with low levels of androgen to
“superactivate” this pathway (Craft et al.
1999). HER-2/neu overexpression often
occurs in advanced prostate cancers (Ady et al.
2004), and stimulates growth and PSA over-
production (Craft et al. 1999). Thus, increased
expression of HER-2/neu in prostate cancer
cells allows androgen-independent growth
(Craft et al. 1999; Culig and Bartsch 2006). 
Inorganic arsenic, a common environmen-
tal contaminant and human carcinogen
[International Agency for Research on Cancer
(IARC) 2004; National Research Council
(NRC) 1999; National Toxicology Program
(NTP) 2000], has been associated with human
prostate cancer (Chen and Wang 1990; Lewis
et al. 1999; NRC 1999; Wu et al. 1989). In
addition, we have shown that arsenic can pre-
cipitate events leading to malignant transfor-
mation of human prostate epithelial cells
in vitro (Achanzar et al. 2002) and can affect
prostate cancer cell progression (Benbrahim-
Tallaa et al. 2005b). In this regard, the immor-
talized, nontumorigenic human prostate
epithelial cell line (RWPE-1) is malignantly
transformed by chronic low-level arsenic to
produce CAsE-PE (chronic arsenic–exposed
prostate epithelial) cells which form tumors
resembling aggressive prostate carcinoma on
injection into nude mice (Achanzar et al.
2002) and show characteristics of advanced,
androgen-independent prostate cancer
(Benbrahim-Tallaa et al. 2005b). Arsenic-
induced androgen independence in CAsE-PE
cells is not associated with AR overexpression
or any apparent loss of ligand specificity
(Benbrahim-Tallaa et al. 2005b), indicating
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BACKGROUND: Prostate cancer progression often occurs with overexpression of growth factors and
receptors, many of which engage the Ras/mitogen-activated protein MAP kinase (MAPK) pathway. 
OBJECTIVES: In this study we used arsenic-transformed human prostate epithelial cells, which also
show androgen-independent growth, to study the possibility that chronic activation of Ras/MAPK
signaling may contribute to arsenic-induced prostate cancer progression. 
METHODS: Control and chronic arsenic–transformed prostate epithelial cells (CAsE-PE) were com-
pared for Ras/MAPK signaling capacities using reverse transcription–polymerase chain reaction and
Western blot analyses. 
RESULTS: We found activation of HER-2/neu oncogene in transformed CAsE-PE cells, providing
molecular evidence of androgen independence in the transformed cells. CAsE-PE cells displayed
constitutively increased expression of unmutated K-Ras (6-fold), and the downstream MAP kinases
A-Raf and B-Raf (2.2-fold and 3.2-fold, respectively). There was also increased expression of phos-
phorylated MEK1/2 and Elk1 in the transformant cells. The MEK1/2 inhibitor, U0126, blocked
PSA overexpression in CAsE-PE cells. 
CONCLUSION: Thus, arsenic-induced malignant transformation and acquired androgen indepen-
dence are linked to Ras signaling activation in human prostate epithelial cells. Chronic activation of
this pathway can sensitize the androgen receptor to subphysiologic levels of androgen. This may be
important in arsenic carcinogenesis and provide a mechanism that may be common for prostate
cancer progression driven by diverse agents.
KEY WORDS: androgen-independent, androgen receptor, arsenic, cancer progression, hormone refractory,
malignant transformation, MAP kinase, prostate, Ras. Environ Health Perspect 115:243–247(2007).
doi:10.1289/ehp.9630 available via http://dx.doi.org/ [Online 20 November 2006]that arsenic impacts progression through other
mechanisms. Importantly, wild-type K-Ras
activation was strongly correlated with arsenic-
induced transformation in CAsE-PE cells
(Benbrahim-Tallaa et al. 2005a). In this
regard, Ras is a component of virtually all the
signaling pathways shown to be up-regulated
in advanced prostate cancer (Hoa et al. 2002;
Rizos et al. 1999; Yu et al. 1993). Although
Ras is infrequently mutated in prostate cancer,
overexpression of wild-type Ras can be sufﬁ-
cient to induce malignant transformation in
human prostate epithelial cells (Weber and
Gioeli 2004). 
Thus, the present study investigated in
detail the molecular mechanism by which
arsenic impacts prostate tumor cell progression
using CAsE-PE cells. The results indicate that
overexpression of HER-2/neu and K-Ras,
resultant mitogen-activated protein kinase
(MAPK) pathway activation and downstream
Raf activation are prominent features. Thus, it
appears arsenic-induced malignant transfor-
mation precipitates up-regulation of Ras,
which in turn allows a by-pass of AR to
induce androgen independence in human
prostate epithelial cells. 
Material and Methods
Chemicals and reagents. We purchased
sodium arsenite (NaAsO2) from Sigma
Chemical Co. (St. Louis, MO), and kera-
tinocyte serum-free medium (K-SFM), epi-
dermal growth factor (EGF), bovine pituitary
extract (BPE), 100 X antibiotic-antimycotic
mixture, and TRIzol Reagent from Life
Technologies, Inc. (Grand Island, NY). The
mouse monoclonal anti-K-Ras and the mouse
monoclonal anti-actin were purchased from
Oncogene Research Products (Cambridge,
MA). We purchased the rabbit polyclonal
anti-HER-2/Erb2, anti-A-Raf, anti-B-Raf,
anti-MEK1/2, anti-Elk1, and horseradish per-
oxidase-conjugated secondary antibody from
Cell Signaling Technology (Beverly, MA),
and the Bradford Protein Assay from Bio-Rad
Laboratories (Hercules, CA).
Cells and cell culture. Control (untrans-
formed) RWPE-1 cells were originally derived
from normal human prostate epithelial cells
and are immortalized but nontumorigenic
(Bello et al. 1997; Webber et al. 1997). Unless
otherwise noted, cells were grown in K-SFM
containing 50 μg/mL BPE and 5 ng/mL EGF,
supplemented with antibiotic/antimycotic
mixture. K-SFM containing BPE and EGF is
henceforth termed “complete medium.” The
steroid-reduced media is deﬁned as a medium
without complement. The BPE is likely the
major source of steroids in complete medium.
Cultures were incubated at 37°C in a humidi-
ﬁed atmosphere containing 5% carbon diox-
ide and passaged weekly. Cells were exposed
continuously to 5 μM arsenite (as sodium
arsenite). The arsenic-exposed cells were
designated as CAsE-PE cells to distinguish
them from the parental control cells. Parallel
cultures grown in arsenic-free medium pro-
vided passage-matched controls. At 29 weeks
of exposure, CAsE-PE cells produce malig-
nant tumors after inoculation into nude mice
(Achanzar et al. 2002). We previously showed
that a clear transition from the androgen-
sensitive to androgen-independent state
occurs during arsenic-induced malignant
transformation of human prostate epithelial
cells (Benbrahim-Tallaa et al. 2005b). 
RNA extraction and RT-PCR. We isolated
total RNA using TRIzol reagent by manufac-
turer’s instructions. Reverse transcription–
polymerase chain reaction (RT–PCR) was
performed using a TITANIUM one-step kit
(Clontech, San Jose, CA) and a GeneAmp
PCR system 9700 (Applied Biosystems,
Foster City, CA) according to the kit’s
instructions. Ampliﬁcation conditions were as
follows: 60 min at 50°C and 5 min at 94°C
followed by 35 cycles each for 1 min at 94°C,
1 min at 54°C, 1 min at 72°C. We used 1 μg
of total RNA in each amplification. Primers
were designed for PSA and β-actin and were
synthesized by Invitrogen as follows: PSA (5´-
GAGGTCCACACACTGAAGTT-3´ and
5´-CCTCCTGAAGAATCGATTCCT-3´),
product size: 214 bp; β-actin (5´-AGA-
GATGGCCACGGCTGCTT-3´ and 5´-
ATTTGCGGTGGACGATGGAG-3´),
product size: 460 bp. PCR products were elec-
trophoresed on 1.7% agarose gels and the gel
image captured and quantiﬁed with a Gel Doc
2000 System equipped with TDS Quantity
One software (Bio-Rad Laboratories). The
level of β-actin was used to normalize results.
Western blot analysis. We isolated total
proteins using M-PER reagent (Pierce,
Rockford, IL) as directed by the manufacturer.
We determined protein concentration using
the Bradford assay, and 20–40 μg of each sam-
ple were electrophoresed and transferred to
nitrocellulose membranes (Invitrogen).
Immunoblotting was performed using the
human K-Ras antibody at a 1:1,000 dilution;
horseradish peroxidase–conjugated anti-
mouse secondary antibody at a 1:5,000 dilu-
tion; HER-2/neu antibody at 1:1,000
dilution; A-Raf antibody at 1:1,000 dilution;
B-Raf antibody at 1:1,000 dilution; Phospho-
MEK1/2 antibody at 1:1,000 dilution; and
phospho-Elk1 antibody at 1:1,000 dilution;
horseradish peroxidase–conjugated anti-rabbit
secondary antibody at a 1:5,000 dilution; and
SuperSignal West Pico Chemiluminescent
Substrate (Pierce). Signals were visualized by
exposure to Hyperﬁlm (Amersham). Densito-
metric analysis was performed using Quantity
One software (Bio-Rad).
Statistical analysis. All data are repre-
sented as mean ± SE derived from three or
more independent experiments. Statistical
significance was determined by the Student
t-test or ANOVA followed by Dunnett’s t-test
as appropriate, with p ≤ 0.05 considered statis-
tically signiﬁcant.
Results
AR activity and malignant transformation
leading to acquired androgen independence.
Arsenic precipitates events leading to rapid
growth and greatly reduced androgen depen-
dence during malignant transformation of
human prostate epithelial cells in vitro
(Benbrahim-Tallaa et al. 2005a, 2005b). AR
expression or ligand speciﬁcity played a mini-
mal role in this arsenic-induced prostate can-
cer cell progression (Benbrahim-Tallaa et al.
2005b). In fact, AR was expressed at essen-
tially the same level in both control and
CAsE-PE cells (Benbrahim-Tallaa et al.
2005b). To further assess the activity of AR in
these cells, we examined androgen-induced
gene expression through AR stimulation. In
this case we examined PSA expression, which
is activated by androgens through AR. As is
typical with prostate malignancies, CAsE-PE
cells expressed significantly more PSA
(2.1-fold, p < 0.05) than control cells (Figure 1).
However, compared with respective untreated
cells, a marked 3.5-fold increase in cellular
PSA mRNA levels occurred with dihy-
drotestosterone (DHT) treatment in control
RWPE-1 cells, whereas levels increased only
0.8-fold in CAsE-PE cells. Indeed, DHT-
induced increases in PSA were to a signifi-
cantly lower maximal level in CAsE-PE cells
compared with control cells (Figure 1). Thus,
AR overexpression was clearly not required
for the steroid-independent growth in CAsE-
PE cells. Because androgen-independent
prostate cancers often become resistant to
antiandrogens, we tested the effect of the
antiandrogen flutamide on DHT-stimulated
PSA mRNA levels in control and CAsE-PE
cells. A DHT-stimulated PSA mRNA level
was completely suppressed by flutamide in
control cells (Figure 1). On the other hand, in
CAsE-PE cells the androgen-stimulated PSA
secretion was blocked only partially by flu-
tamide. Collectively, CAsE-PE cells responded
differently to DHT and flutamide, both of
which are thought to act through direct inter-
action with AR. 
HER-2/neu activation with arsenic-
induced acquired androgen independence.
Several reports have described the involvement
of HER-2/neu tyrosine kinase—a type I
growth factor receptor tyrosine kinase—in acti-
vating the AR through the MAPK pathway
(Ady et al. 2004; Craft et al. 1999), and
HER-2/neu expression has been implicated in
the progression of prostate cancer to a hor-
mone independence (Yeh et al. 1999; Wen
et al. 2000). Therefore, the level of HER-2/neu
Benbrahim-Tallaa et al.
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compared with androgen-independent,
arsenic-transformed CAsE-PE cells (Figure 2).
HER-2/neu protein in transformed CAsE-PE
cells was expressed at levels > 400% greater
than control. This is consistent with the
aggressive nature and androgen independence
of CAsE-PE cells.
Arsenite enhances K-Ras gene expression
during malignant transformation. Because
Ras-related pathways are often related to
androgen independence in prostate cancer, this
potential oncogene was studied in detail. K-Ras
protein level in CAsE-PE cells was greatly
increased (6-fold) compared with control
(Figure 3). We previously showed that K-Ras
overexpression precedes and remains elevated
with malignant transformation of CAsE-PE
cells (Benbrahim-Tallaa et al. 2005a).
MAPK pathway correlates with prostate
cancer cell progression. Ras is a critical signaling
molecule that controls several signaling path-
ways in prostate cancer. One of the best-
characterized effector pathways trigged by Ras
activation is the MAPK pathway (Figure 4).
Thus, events downstream of Ras in CAsE-PE
cells were compared with control RWPE-1.
Clearly, proteins downstream of K-Ras, includ-
ing A-Raf and B-Raf (both serine–threonine
MAP kinases) showed greatly increased expres-
sion in CAsE-PE cells compared with control
(2.6- and 3.1-fold, respectively) (Figure 5A).
There was also an increased expression of phos-
phorylated MEK1/2 and ELK in CAsE-PE
cells compared with control (Figure 5B). Thus,
there is a correlation between elevated levels of
active phospho-MAPK and arsenic-induced
prostate cell transformation. Also, treatment
with the specific MEK inhibitor, U0126,
inhibited PSA expression up to 80% in CAsE-
PE cells (Figure 6).
Discussion
The normal development, growth, and survival
of the prostate epithelium is regulated both by
androgen and by the paracrine production of
growth factors by the prostatic stroma
(Feldman and Feldman 2001). However, regu-
latory interactions between androgens and
growth factors often become distorted in
prostate cancer. Early-stage prostate cancer typ-
ically requires androgen for growth and thus
responds to androgen ablation (Feldman and
Feldman 2001). However,following such ther-
apy, the disease often progresses to an andro-
gen-independent state, rendering androgen
ablationineffective (Arnold and Isaacs 2002). 
Progression of prostate cancer to the fre-
quently fatal androgen-independent disease is
often associated with the elevation and
autocrine production of multiple polypeptide
growth factors (Gioeli et al. 1999). For exam-
ple, EGF, transforming growth factor α,
insulin-like growth factor 1, interleukin 6,
keratinocyte growth factor, and other ﬁbrob-
last growth factor family members are
expressed in advanced prostate cancers and
are believed to be important in fueling andro-
gen-independent growth (Culig et al. 1994;
Yeh et al. 1999). Among compounds that
activate AR function in the absence of ligand
or in a synergistic manner with low androgen
levels, it appears the EGF receptor-related
molecule, HER-2/neu, plays a critical role
(Craft et al. 1999). A type I growth factor
receptor tyrosine kinase, HER-2/neu is over-
expressed in most epithelial malignancies
(Carles et al. 2004; Ren et al. 2005; Wu et al.
2004). HER-2/neu overexpression results in
enhanced growth of prostate cancer and up-
regulation of PSA (Craft et al. 1999; Shi et al.
2006; Veeramani et al. 2005). Our results
showed that CAsE-PE cells greatly overex-
press HER-2/neu compared with control in
association with malignant transformation
and acquired androgen independence.
HER-2/neu production is positively regulated
by androgens in androgen-dependent LNCaP
prostate cancer cells (Zhau et al. 1992). A
transmembrane tyrosine kinase, HER-2/neu,
triggers intracellular signaling cascades such as
MAP and Akt kinase pathways (Culig 2004;
Wen et al. 2000). Importantly, HER-2/neu
promotes phosphorylation of AR at multiple
sites, which results in a highly active tran-
scriptional unit even in the presence of low
androgen levels (Culig 2004; Sugita et al.
2004). Thus, it appears HER-2/neu activa-
tion is a key factor in arsenic-induced
acquired androgen independence in malig-
nant human prostate epithelial cells.
Because Ras/MAPK signaling can reduce
the androgen requirement of prostate cancer
cells (Bakin et al. 2003b), one would predict
that stimulation of this signaling pathway
Arsenic-induced androgen independence
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Figure 1. The effect of ﬂutamide on the PSA mRNA
expression of control RWPE-1 and CAsE-PE cells.
Control and CAsE-PE were grown in complete
medium. After 48 hr in steroid-reduced medium
deﬁned as K-SFM without BPE and EGF, cells were
fed with fresh steroid-reduced medium with or
without 5 µg/mL flutamide in the presence or
absence of 0.1 µM DHT. RNA was isolated and
subjected to RT-PCR analysis using a set of
primers designed to amplify PSA and β-actin gene
products. PCR products were separated on a 1.7%
agarose gel. The data shown are expressed as
means (n = 3); error bars represent SE. 
*Significantly different from untreated, cell-line–matched
cells. **Significantly different from control cells treated
with DHT or DHT plus ﬂutamide.
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Figure 2. Analysis of the effect of chronic arsenic
exposure of prostate epithelial cells on HER-2/neu
protein expression. CAsE-PE cells were ﬁrst derived
by exposing RWPE-1 cells to 5 µM sodium arsenite
for 30 weeks. Proteins were isolated from control
and arsenic-transformed CAsE-PE cells and sub-
jected to Western blot analysis. Upper panel is a
representative blot, whereas the lower panel is
densitometric analysis normalized to β-actin.
Densitometric data are given as fold-control and
expressed as means (n = 3); error bars represent SE. 
*Signiﬁcantly different from control.
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Figure 3. Analysis of the effect of chronic arsenic
exposure of prostate epithelial cells on K-ras protein
expression. CAsE-PE cells were first derived by
exposing RWPE-1 cells to 5 µM sodium arsenite for
30 weeks. Proteins were isolated from control and
arsenic-transformed CAsE-PE cells and subjected to
Western blot analysis. Upper panel is a representa-
tive blot, whereas the lower panel is densitometric
analysis normalized to β-actin. Densitometric data
are given as fold-control and expressed as means
(n = 3); error bars represent SE. 
*Signiﬁcantly different from control. 
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β-actinmight allow androgen-regulated gene
expression even at very low levels of andro-
gen. Previous studies showed that flutamide
inhibits the androgen-signaling pathway in
androgen-dependent but not refractory
tumors (Ilagan et al. 2005). We measured
endogenous PSA expression as an indicator of
androgen-regulated gene expression. The
antiandrogen ﬂutamide completely abolished
PSA expression in control cells but only par-
tially attenuated PSA production in trans-
formed CAsE-PE cells. This finding is
consistent with an androgen refractory status.
Overexpression of K-Ras and activation of
MAPK correlate with progression in CAsE-PE
cells (Benbrahim-Tallaa et al. 2005a, 2005b).
Similarly, expression of activated Ras makes
LNCaP epithelial prostate cancer cell line less
dependent on androgens (Bakin et al. 2003b).
Also, expression of dominant negative Ras
restores androgen dependence to C4-2 cells
(Bakin et al. 2003a). C4-2 is a hormone-
refractory derivative of the LNCaP cell line
(Wu et al. 1994). Our work in vitro shows
that the common environmental contaminant
arsenic can induce malignant transformation
associated with androgen independence in
human prostate epithelial cells (Achanzar et al.
2002; Benbrahim-Tallaa et al. 2005b).The
increase in MAPK activation in androgen-
independent CAsE-PE cells in the present
study is consistent with the hypothesis that
prostate cancer progression induced by arsenic
is associated with chronic stimulation of the
Ras signaling pathway.
Treatment of cells with the MAPK
inhibitorU0126 totally abolished PSA expres-
sion in CAsE-PE cells but only partially in
control cells. PSA expression is normally con-
trolled by androgen through AR. Because
androgen-refractory CAsE-PE cells greatly
overexpress PSA, these results clearly show
MAPK activity is critical to arsenic-induced
acquired androgen independence. This forti-
fies the concept that events downstream of
AR are of critical importance to arsenic-
induced prostate cancer progression.
In summary, this study indicates that
arsenic-induced malignant transformation
and acquired androgen independence in
human prostate epithelial cells is associated
with an apparent “by-pass” of the androgen
requirement for AR pathway activation. The
most likely basis of this androgen indepen-
dence is overexpression of HER-2/neu.
Activation of the Ras/MAPK pathway in
CAsE-PE cells correlates with this progression
Benbrahim-Tallaa et al.
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Figure 6. The effect of U0126, a MEK inhibitor, on
PSA expression in control RWPE-1 and CAsE-PE
cells. Control and CAsE-PE were grown in complete
medium in the presence or absence of 20 µM U0126.
RNA was isolated and subjected to RT-PCR analysis
using a set of primers designed to amplify PSA and
β-actin gene products. PCR products were sepa-
rated on a 1.7% agarose gel. Results are normalized
to β-actin. The data shown are expressed as means
(n = 3); error bars represent SE. 
*Significantly different from untreated, cell-line–matched
cells. **Significantly different from control cells treated
with U0126.
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Figure 5. Analysis of the effect of chronic arsenic exposure of prostate epithelial cells on MAPK activation.
ELK, E-26-like protein-1. CAsE-PE cells were ﬁrst derived by exposing RWPE-1 cells to 5 µM sodium arsenite
for 30 weeks. Proteins were isolated from control and arsenic-transformed CAsE-PE cells and subjected to
Western blot analysis. (A) A- and B-Raf protein expression. (B) MEK1/2 and ELK-1 MAPK activation. Upper
panel is a representative blot, whereas the lower panel is densitometric analysis normalized to β-actin.
Densitometric data are given as fold-control and expressed as means (n = 3); error bars represent SE. 
*Signiﬁcantly different from control. 
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Figure 4. MAPK pathway. Abbreviations: GPCR, G protein coupled receptors; GTPase, guanosine triphos-
phatases. MAPK are a family of serine–threonine protein kinases widely conserved among eukaryotes
and are involved in many cellular programs such as cell proliferation, cell differentiation, cell movement,
and cell death. MAPK signaling cascades are organized hierarchically into three-tiered modules. MAPKs
(Erk) are phosphorylated and activated by MAPK-kinases (MAPKKs), (MEK1/2), which in turn are phospho-
rylated and activated by MAPKK-kinases (MAPKKKs), (Raf). The MAPKKKs are in turn activated by inter-
action with the family of small GTPases and/or other protein kinases (Ras, Rap1), connecting the MAPK
module to cell surface receptors or external stimuli. An activated Erk dimer can regulate targets in the
cytosol and also translocate to the nucleus where it phosphorylates a variety of transcription factors regu-
lating gene expression. 
Growth factors,
mitogens, GPCR
Ras
Active-Ras
Stimuli MAPKKK MAPKK MAPK
A-Raf, B-Raf,
e-Raf, Mos, Tpl2 MEK 1/2 ERK 1/2
Growth
differentiation
development
Biological
responseto androgen independence. Indeed, blockage
of MAPK inhibited androgen-regulated gene
expression, highlighting the role of Ras-
directed signaling pathways in arsenic-induced
androgen independence. These observations
indicate that this important and common envi-
ronmental contaminant can potentially stimu-
late both initiation and progression of human
prostate cancer. Progression to androgen inde-
pendence is a key factor in the eventual mortal-
ity from this all too common malignancy.
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